News ASCO 25: Merus bispecific scores again in HNSCC For the second year running, data at ASCO on Merus' bispecific antibody petosemtamab in head and neck cancer has drawn the eye.
News ASCO 25: Can GLP-1 drugs reduce cancer risk? A study has suggested the benefits of GLP-1 agonists could extend to a reduction in the risk of a slew of cancers associated with being overweight.
News ASCO 25: Jazz, PharmaMar reveal SCLC survival data Jazz and PharmaMar have revealed the overall survival data with their small-cell lung cancer drug Zepzelca, described as a 'milestone' in the disease.
News ASCO 25: Roche places Itovebi marker in breast cancer Roche's Itovebi has become the first PI3K inhibitor to extend survival in HR-positive, HER2-negative breast cancer with a PIK3CA mutation.
News Mixed outcomes for pharma in big week for FDA adcomms There was good news for Johnson & Johnson at this week's ODAC meetings, but not for Roche, UroGen, and Pfizer.
News UK trumpets £1bn investment plan from BioNTech BioNTech has said it will commit up to £1bn in investment in the UK over the next decade, in what has been described as a "template" for the sector.
News Ambrosia's sweet $100m round, and other biofinancings Our latest crop of biofinancings has a nine-figure round for Ambrosia, with Pinnacle Medicines, Immutrin, and Gilgamesh Pharma also raising new funds.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
